Table 17Yellowing of the Skin Among Beta-Carotene Studies

StudyComparisonMean followup (y)# of events among participants receiving beta carotene (%)# of events among participants not receiving beta carotene (%)
ATBC59Beta-carotene vs. no beta carotene6.14,950/14,560 (34)1,020/14,573 (7)
PHS-I61Beta-carotene vs. no beta carotene121,745/11,036 (15.8)1,535/11,035 (13.9)
WHS62Beta-carotene vs. no beta carotene4.12,131/19,937 (10.7)1,944/19,939 (9.7)
SCPS63*Beta-carotene vs. placebo512/913 (1.3)0/892 (0)
CARET60Beta-carotene + vitamin A vs. placebo428/9,420 (0.3)NR
*

Reported among participants who stopped taking the study capsules due to capsule-related symptoms.

Skin yellowing of grade 3 or higher (grade 1 representing normal or no symptoms; grades 4–5 representing severe symptoms).

Abbreviations: ATBC = Alpha-Tocopherol Beta-Carotene Cancer Prevention; CARET = Carotene and Retinol Efficacy Trial; NR = not reported; PHS-I = Physician's Health Study I; SCPS = Skin Cancer Prevention Study; WHS = Women's Health Study; y = years.

Reported among participants who stopped taking the study capsules due to capsule-related symptoms.

Skin yellowing of grade 3 or higher (grade 1 representing normal or no symptoms; grades 4–5 representing severe symptoms).

From: 3, Results

Cover of Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer
Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 108.
Fortmann SP, Burda BU, Senger CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.